"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of everolimus for advanced stomach cancer (GRANITE-1)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at everolimus for cancer of the stomach that has continued to grow despite chemotherapy or has come back after treatment.
In this trial, they looked at a drug called everolimus to see if it can help people in this situation.
Everolimus is a type of biological therapy. It is also known as RAD 001 or Afinitor. It was first developed for people who have had a heart or kidney transplant. It helps to stop the body rejecting the new organ. But we know from research that everolimus may also help to stop cancer cells growing.
The aim of this trial was to see if everolimus helps people with advanced stomach cancer.
Summary of results
The trial team found that everolimus did not help people with advanced stomach cancer that had continued to grow or had come back after chemotherapy.
This trial recruited 656 people from 23 countries. The people taking part were put into 1 of 2 treatment groups at random. They either had everolimus or a dummy drug (placebo). Everyone taking part also had treatment they needed for their specific symptoms. Doctors often call this best supportive care.
For every 2 people who had everolimus, 1 person had the dummy drug. So
- 439 people had best supportive care and everolimus
- 217 people had best supportive care and the dummy drug
The research team looked at how long it was on average before the cancer started to grow again. They found it was
- 1.7 months for those who had everolimus
- 1.4 months for those who had the dummy drug
They also looked at how long on average people in each group lived for, and found it was
- 5.4 months for those who had everolimus
- 4.3 months for those who had the dummy drug
There is a small difference between the 2 groups, but it could have happened by chance. The results were not
Nearly everyone taking part had at least one side effect. The most common side effects were loss of appetite, sore mouth, tiredness (fatigue) and feeling sick.
The research team concluded that everolimus did not help people with advanced stomach cancer who had already had chemotherapy.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor David Cunningham
NIHR Clinical Research Network: Cancer